Ubs Group Ag Phio Pharmaceuticals Corp. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.33 - $63.51 $7,599 - $1.46 Million	23,029 New	23,029 $8,000
Q2 2022 Aug 10, 2022	SELL	$0.64 - $2.35 $1,718 - $6,309	-2,685 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.73 - $1.1 $3,149 - $4,746	-4,315 Reduced 61.64%	2,685 $2,000
Q4 2021 Feb 14, 2022	BUY	$0.99 - $1.99 $751 - $1,510	759 Added 12.16%	7,000 $7,000
Q3 2021 Nov 15, 2021	BUY	$1.62 - $2.28 $7,879 - $11,089	4,864 Added 353.23%	6,241 $13,000
Q2 2021 Aug 13, 2021	BUY	$1.87 - $2.8 $2,574 - $3,855	1,377 New	1,377 $3,000
Q1 2021 May 12, 2021	SELL	$2.48 - $4.05 $13,945 - $22,773	-5,623 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$2.01 - $3.32 $10,164 - $16,789	5,057 Added 893.46%	5,623 $15,000
Q3 2020 Nov 12, 2020	SELL	$1.95 - $2.94 $20,656 - $31,143	-10,593 Reduced 94.93%	566 $1,000
Q2 2020 Jul 31, 2020	BUY	$1.68 - $3.05 $17,801 - $32,317	10,596 Added 1882.06%	11,159 $24,000
Q1 2020 May 01, 2020	BUY	$1.77 - $12.93 $996 - $7,279	563 New	563 $1,000

Ticker PHIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,658,700
Market Cap $30.2M
Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.